Press Releases
Novel PTSD Treatment Advances Toward Regulatory Evaluation with New Collaboration
On PTSD Awareness Day, MAPS PBC announces plans to develop the New Drug Application for MDMA-assisted therapy in collaboration with MMS Holdings The second Phase 3 trial of the Breakthrough-Designated Therapy for PTSD will be completed in late 2022, with a targeted...
MAPS Appoints Jeff George and Dan Grossman to MAPS PBC Board of Directors
Experienced healthcare leaders bring decades of experience in global drug commercialization and patient access Appointment brings significant pharmaceutical leadership experience to the MAPS PBC board MDMA-assisted therapy, a novel treatment for PTSD with FDA...
MAPS Completes Enrollment, as Planned, for the Confirmatory Phase 3 Trial of MDMA-Assisted Therapy for PTSD
FOR IMMEDIATE RELEASE: May 9, 2022 The second, confirmatory Phase 3 trial of MDMA-assisted therapy for PTSD is now fully enrolled at 13 sites in the United States and Israel Completion of enrollment on schedule supports targeted submission of the New Drug Application...
Michael Mullette Joins MAPS PBC Senior Leadership as Chief Operating Officer
Former Moderna Vice President and Managing Director for North America recruited to prepare MAPS PBC for patient access and commercialization of the first psychedelic-assisted therapy anticipated to be approved by the FDA Hire represents a major step forward in...
MAPS PBC Adopts Charter for Independent Ethics Review Board
FOR IMMEDIATE RELEASE Independent members will inform continual iteration and improvement of ethical governance of MDMA-assisted therapy research and therapist training program Independent Ethical Review Board engages outside experts to provide additional layer of...
MAPS Receives Grant of Appeal and Authorization to Study MDMA in Healthy Volunteer Therapists
Phase 1 clinical trials of MDMA-assisted therapy for healthcare providers will measure development of self-compassion, professional quality of life, and professional burnout among clinicians delivering the treatment to patients The study, one of few legal means by...
MAPS’ Phase 3 Trial of MDMA-Assisted Therapy for PTSD Achieves Highly Statistically Significant Results for Patients with Severe, Chronic PTSD
The highly statistically significant results and excellent safety record suggest MDMA-assisted therapy will be an effective treatment for severe, chronic PTSD 67% of participants who received three MDMA-assisted therapy sessions no longer qualified for a PTSD...
First Controlled Trial of Cannabis for the Treatment of PTSD Raises no Safety Concerns, Further Research is Needed to Determine Efficacy
Widespread anecdotal reports of benefit have led to self-treatment of the symptoms of posttraumatic stress disorder (PTSD) with cannabis among Veterans and others; the safety and potential efficacy of such treatments have not previously been studied through randomized...
MAPS Public Benefit Corporation Expands Talent with Three Leadership Hires
MAPS Public Benefit Corporation (MAPS PBC), a wholly-owned subsidiary of the Multidisciplinary Association of Psychedelic Studies (MAPS), has recently expanded their team with three new leaders bringing decades of...
MAPS-Sponsored Pilot Study: MDMA-Assisted Psychotherapy for PTSD in Couples May Reduce PTSD Symptoms, Improve Couples’ Happiness
Cognitive-behavioral conjoint therapy (CBCT) for posttraumatic stress disorder (PTSD), when combined with MDMA, resulted in significant improvements in PTSD symptoms Six couples, in which one partner was diagnosed with PTSD, participated in a seven-week protocol; both...